Macrogenics (MGNX) Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. BIIB
7. CMG
8. TENB
9. KLAC
10. ETSY

Go back to Macrogenics (MGNX) Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

April 3, 2024 4:30 PM EDT

Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data, including safety and preliminary efficacy, by May 31Company plans to provide additional clinical data including rPFS in the Fall of 2024

ROCKVILLE, MD, April 03, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the Phase 2 TAMARACK study of vobramitamab... More